PACTR202201655513401

Efficacy and safety of four-weeks versus twelve-weeks loading doses spacing of intravitreal Aflibercept for treatment of macular edema associated with Central Retinal Vein Occlusion

Egypt health insurance·Not Applicable·Pan Africa Clinical Trials Registry·drugRecruitment Completed
Study focus
Disease/Condition
Eye Diseases
Intervention type
drug
Sponsor & location
Primary sponsor
Egypt health insurance
Location
Egypt
Timeline & enrollment
Phase
Not Applicable
Start date
Jan 01, 1900
End date
Jan 01, 1900
Summary

The proposed research aims to answer the question about efficacy and safety of 4 weeks versus 12 weeks spacing of loading doses of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion. The 4 weeks spacing is the conventional injection protocol used by many centres of injection worldwide. The 12 weeks spacing is used only in Egyptian General Authority for Health Insurance hospitals based on evidence reported in the literature that post aflibercept injection macular edema-free interval was as long as eight weeks or more. A randomized clinical trial will be conducted to answer the question and tell us which strategy results in better vision with lower number of injections after the one year follow up interval of those patients. aims of study: At the end of the study, in which group the patients received a smaller number of injections with better visual acuity. At the end of study, in which group, the patients received a smaller number of injections with best central macular thickness reduction documented by Heidelberg Spectralis Optical coherence tomography (OCT).

ICD-10 classifications
Disorders of eyelid in diseases classified elsewhereOther disorders of eyelidOther specified disorders of eyelidInvolvement of eyelid in other diseases classified elsewhereDisorder of eyelid, unspecified
Data source
Registry
Pan Africa Clinical Trials Registry
Trial ID
PACTR202201655513401
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for PACTR202201655513401 through Pure Global AI's free database. This Not Applicable trial is sponsored by Egypt health insurance and is currently Recruitment Completed. The study focuses on Eye Diseases.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Pan Africa Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.